Pharma 2020: Marketing the Future

In the 1990s, most of the medicines Pharma made were primary-care therapies for diseases afflicting large patient populations, such as hypertension, diabetes, high cholesterol and depression. But genomics, proteomics and metabolomics are providing new tools with which to develop larger […]

Read More

A New Business Model for Pharma Innovation

If the pharmaceutical industry is to design a more optimal R&D model for the future to improve productivity, it needs to look beyond its own boundaries to other IP-rich technology environments. Big Pharma traditionally has been characterized by a ‘closed […]

Read More

Leading in Challenging Times

Managers in the life science industry, with its inherent “all or nothing” R&D requirements and rapidly changing regulatory environment, may sometimes feel they are in a state of constant crisis. The simple fact is that challenges are always coming—but times […]

Read More